Diabetes
WT817
Bifunctional RNA targeting pancreatic beta islet cell delivering siRNA to p57kip2, allowing for regeneration of these cells.
Precision Targeting Using RNA
We are advancing a pipeline of modified RNA therapeutics in order to treat, and potentially cure, deadly diseases such as diabetes and cancer.
Platform Discovery
At WiNK, we are pioneering treatment approaches for diabetes and solid tumors through our innovative modified RNA aptamer therapeutics. Our initial focus is on Type 1 diabetes, supported by compelling proof-of-concept data showing that our bifunctional RNA therapeutics precisely target human pancreatic beta islet cells. Our flagship assets, WT817 and WT931, uniquely enable beta cell regeneration and protection—an unprecedented breakthrough in the pharmaceutical industry for a non-cell-based treatment modality.
INDICATION
TYPE 1 DIABETES
ASSET
WT817
PRECLINICAL
INDICATION
TYPE 1 DIABETES
ASSET
WT931
PRECLINICAL
INDICATION
ONCOLOGY
ASSET
TIMC Platform
PRECLINICAL
INDICATION
TYPE 1 DIABETES
TYPE 1 DIABETES
ONCOLOGY
ASSET
WT817
WT931
TIMC Platform
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
Diabetes
WT931
Bifunctional RNA targeting pancreatic beta islet cell delivering saRNA of PD-L1, allowing for protection of these cells against autoimmune attack.
Oncology
TIMC Platform
Within the tumor microenvironment, there consists of many immune cells that can either be tumor-promoting or anti-tumor. We have proof-of-concept data demonstrating that we can target the tumor microenvironment of most solid tumors because we can specifically target tumor-promoting cells in a highly specific manner, thus using them as a ‘trojan horse’ to deliver payloads to that tumor microenvironment.
